CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:
NDA 20-164/S-044

Name: Lovenox® (Enoxaparin Sodium) Injection

Sponsor: Aventis Pharmaceuticals Products, Inc.

Approval Date: November 30, 2001
APPLICATION NUMBER:
NDA 20-164/S-044

CONTENTS

<table>
<thead>
<tr>
<th>Reviews / Information Included in this Review</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval Letter</td>
<td>X</td>
</tr>
<tr>
<td>Approvable Letter</td>
<td></td>
</tr>
<tr>
<td>Labeling</td>
<td></td>
</tr>
<tr>
<td>Labeling Reviews</td>
<td></td>
</tr>
<tr>
<td>Medical Review</td>
<td></td>
</tr>
<tr>
<td>Chemistry Review</td>
<td>X</td>
</tr>
<tr>
<td>Pharmacology / Toxicology Review</td>
<td></td>
</tr>
<tr>
<td>Statistical Review</td>
<td></td>
</tr>
<tr>
<td>Microbiology Review</td>
<td>X</td>
</tr>
<tr>
<td>Clinical Pharmacology / Biopharmaceutics Review</td>
<td></td>
</tr>
<tr>
<td>Administrative and Correspondence Documents</td>
<td>X</td>
</tr>
</tbody>
</table>
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
NDA 20-164/S-044

APPROVAL LETTER
NDA 20-164/S-044

Aventis Pharmaceuticals Inc.
Attention: Joseph A. Carrado, M.Sc., R.Ph.
Global Drug Regulatory Affairs
Global Therapeutic Area head
Route 202-206, P.O. Box 6800
Bridgewater, NJ 08807-0800

Dear Mr. Carrado:

Please refer to your supplemental new drug application dated May 31, 2001, received
June 1, 2001, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for
Lovenox® (enoxaparin sodium) Injection.

This supplemental application, submitted as a “Supplement – Changes Being Effected in 30 days”
supplement, provides for the following change: an increase in the Lovenox Injection formulation batch
size to ——— for Line ——(Maisons-Alfort) used to —— fill the syringe sizes
of 0.6 mL (60 mg), 0.8 mL (80 mg), and 1.0 mL (100 mg) Lovenox Injection.

We have completed the review of this supplemental application, and it is approved.

We remind you that you must comply with the requirements for an approved NDA set forth under
21 CFR 314.80 and 314.81.

If you have any questions, call Karen Oliver, Regulatory Project Manager, at (301) 827-7457.

Sincerely,

Liang Zhou, Ph.D.
Chemistry Team Leader for the
Division of Gastrointestinal and Coagulation Drug
Products, (HFD-180)
DNDC II, Office of New Drug Chemistry
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Liang Zhou
11/30/01 12:53:29 PM
<table>
<thead>
<tr>
<th>CHEMIST'S REVIEW # 1</th>
<th>1. Organization: HFD-180</th>
<th>2. NDA number: 20-164</th>
</tr>
</thead>
<tbody>
<tr>
<td>3. Name and Address of Applicant (City &amp; State):</td>
<td>4. AF Number:</td>
<td></td>
</tr>
<tr>
<td>Aventis Pharmaceuticals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10236 Marion Park Drive, P.O. Box 9627</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kansas City, MO 64134</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Supplement(s)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Name of Drug:</td>
<td>7. Nonproprietary Name:</td>
<td>8. Supplement provides for: the increase in the Lovenox Injection formulation batch size to Line (Maisons-Alfort, France) used to fill the syringe sizes of 0.6 mL (60 mg), 0.8 mL (80 mg) and 1.0 mL (100 mg) Lovenox Injection.</td>
</tr>
<tr>
<td>Lovenox Injection</td>
<td>enoxaparin sodium injection</td>
<td></td>
</tr>
<tr>
<td>Numbers</td>
<td>Dates</td>
<td></td>
</tr>
<tr>
<td>SCS-044</td>
<td>31-May-2001</td>
<td></td>
</tr>
<tr>
<td>anti-thrombotic</td>
<td>RX-XXX OTC</td>
<td>SCS-026 Approved 14-Sep-99</td>
</tr>
<tr>
<td>13. Dosage Form:</td>
<td>14. Potency:</td>
<td></td>
</tr>
<tr>
<td>injection (subcutaneous)</td>
<td>100 mg/mL</td>
<td></td>
</tr>
<tr>
<td>15. Chemical Name and Structure:</td>
<td>16. Records and Reports:</td>
<td></td>
</tr>
<tr>
<td>See USP Dictionary (2001)</td>
<td>Current</td>
<td></td>
</tr>
<tr>
<td>Yes X No</td>
<td>Reviewed</td>
<td></td>
</tr>
<tr>
<td>Yes X No</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17. Comments:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. Aventis notes: &quot;There are no changes to components, composition or packaging for the drug product.&quot; 2. The fifth year Expected Introduction Concentration (EIC) is calculated to be at a level below 1 ppb for the EIC (Adequate). 3. The Microbiologist's review, by Dr. N. Sweeney, recommends for approval for microbiology issues concerning sterility issues. 4. Compliance: EES completed-&quot;Acceptable&quot;. 5. The supplement is for a batch scale-up; no chemistry issues are pending and the supplement is acceptable from a chemistry viewpoint.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>cc: NDA 20-164</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HFD-180/Div File</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HFD-181/CSO/KOliver</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18. Conclusions and Recommendations: Based on the submitted chemistry information, the microbiologist's review, and the FDA CDER EES report, this chemistry reviewer from a chemistry viewpoint recommends that the supplement should be approved. The CSO should prepare an approval letter for the Team Leaders signature.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19. Reviewer</td>
<td>Signature</td>
<td>Date Completed:</td>
</tr>
<tr>
<td>Name: Joseph Sieczkowski, Ph.D.</td>
<td></td>
<td>November 29, 2001</td>
</tr>
</tbody>
</table>
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
-------------------
Joe Sieczkowski
11/29/01 02:13:56 PM
CHEMIST

Liang Zhou
11/29/01 02:29:11 PM
CHEMIST
APPLICATION NUMBER:
NDA 20-164/S-044

MICROBIOLOGY REVIEW
REVIEW FOR HFD-180
OFFICE OF NEW DRUG CHEMISTRY
MICROBIOLOGY STAFF HFD-805
Microbiologist's Review #1 of NDA 20-164/SCS-044

November 16, 2001

A. 1. APPLICATION NUMBER: 20-164/SCS-044

APPLICANT:
Aventis Pharmaceuticals
10236 Marion Park Drive
P.O. Box 9720
Kansas City, MO 64134-9720
Phone: 816-966-5100
FAX: 816-966-6794

2. PRODUCT NAME:
Lovenox Injection

3. DOSAGE FORM AND ROUTE OF ADMINISTRATION: Sterile enoxaparin sodium solution in 30, 40, 60, 80, and 100 mg concentrations in pre-filled syringes for subcutaneous injection.

4. METHODS OF STERILIZATION:

5. PHARMACOLOGICAL CATEGORY and/or PRINCIPLE INDICATION: Low molecular weight heparin indicated for treatment of deep vein thrombosis or pulmonary embolism.

6. DRUG PRIORITY CLASSIFICATION: Standard

B. 1. DATE OF INITIAL SUBMISSION: 5/31/01

2. DATE OF CONSULT: 6/12/01

3. ASSIGNED FOR REVIEW: 6/15/01

4. RELATED DOCUMENTS: NDA 20-164 SCS-026

C. REMARKS: The CBE-30 supplement provides for an increase in batch size (from — — to ———) for the 60 mg/0.6 mL, 80 mg/0.8 mL and 100 mg/1.0 mL pre-filled syringe strengths of Lovenox. NDA 20-164/SCS-026, approved 9/14/99, provided for the ——— batch size for the 30 mg/0.3 mL and 40 mg/0.4 mL pre-filled syringe strengths of Lovenox.
D. CONCLUSIONS:

The submission is recommended for approval for microbiology issues concerning sterility assurance. Specific comments are provided in section "E. REVIEW NOTES".

Neal Sweeney, Ph.D.

cc: NDA 20-164/SCS-044
    HFD-180/Division File
    HFD-180/K. Oliver
    HFD-180/J. Sieczkowski
    HFD-805/Consult File/N. Sweeney

Drafted by:    N. Sweeney, November 16, 2001
R/D initialed by P. Cooney, November 16, 2001
Redacted 3 page(s) of trade secret and/or confidential commercial information from

MICROBIOLOGY REVIEW #1
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
-----------------------
Neal Sweeney
11/28/01 04:13:17 PM
MICROBIOLOGIST

Peter Cooney
11/29/01 11:29:53 AM
MICROBIOLOGIST
APPLICATION NUMBER:
NDA 20-164/S-044

ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS
NDA 20-164/S-044

Aventis Pharmaceuticals
Attention: Dhiren N. Shah, Ph.D.
Director - CMC, US Drug Regulatory Affairs
10236 Marion Park Drive, P.O. Box 9627
Kansas City, MO 64134-0627

Dear Dr. Shah:

We have received your supplemental drug application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for the following:

Name of Drug Product: Lovenox® (enoxaparin sodium) Injection

NDA Number: 20-164

Supplement Number: S-044

Date of Supplement: May 31, 2001

Date of Receipt: June 1, 2001

This supplemental application, submitted as a "Supplement - Changes Being Effected in 30 days" supplement, proposes the following change: increasing the batch size for the 60 mg/0.6 mL, 80 mg/0.8 mL, and 100 mg/1.0 mL Lovenox® Injection pre-filled syringes from ___ to ___

Unless we notify you within 60 days of our receipt date that the application is not sufficiently complete to permit a substantive review, this application will be filed under section 505(b) of the Act on July 31, 2001 in accordance with 21 CFR 314.101(a). If the application is filed, the user fee goal date will be December 1, 2001.

Please cite the application number listed above at the top of the first page of any communications concerning this application. All communications concerning this supplemental application should be addressed as follows:
U.S. Postal/Courier/Overnight Mail:
Food and Drug Administration
Center for Drug Evaluation and Research
Division of Gastrointestinal and Coagulation Drug Products, HFD-180
Attention: Division Document Room, Rm. 6B-24
5600 Fishers Lane
Rockville, Maryland 20857

If you have any questions, call me at (301) 827-7457.

Sincerely,

(See appended electronic signature page)

Karen Oliver
Regulatory Project Manager
Division of Gastrointestinal and Coagulation Drug Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

________________________
Karen Oliver
6/12/01 02:48:11 PM
REQUEST FOR CONSULTATION

DO (Division/Office): HFD-160  
ATTENTION: Dr. Peter Cooney

FROM: HFD-180 (Division of Gastrointestinal and Coagulation Drug Products) Phone # 827-7457

DATE: June 12, 2001  
IND NO.: NDA20-164/S-044  
NDA NO.: NDA 20-164/S-044

TYPE OF DOCUMENT:
- NDA Supplement-044
- CBE

DATE OF DOCUMENT: May 31, 2001  
DATE OF DOCUMENT: May 31, 2001

DESIRED COMPLETION DATE:
- User fee Due Date: 6 mo: 12/01/01

NAME OF DRUG:
- Lovenox (enoxaparin sodium) Injection

PRIORITY CONSIDERATION:
- Standard

CLASSIFICATION OF DRUG:

NAME OF FIRM: Aventis Pharmaceuticals Products Inc.

REASON FOR REQUEST

I. GENERAL

- NEW PROTOCOL
- PROGRESS REPORT
- NEW CORRESPONDENCE
- DRUG ADVERTISING
- ADVERSE REACTION REPORT
- MANUFACTURING CHANGE/ADDITION
- MEETING PLANNED BY

- PRE—NDA MEETING
- END OF PHASE II MEETING
- RISUBMISSION
- SAFETY/EFFICACY
- PAPER NDA
- CONTROL SUPPLEMENT

- RESPONSE TO DEFICIENCY LETTER
- FINAL PRINTED LABELING
- LABELING REVISION
- ORIGINAL NEW CORRESPONDENCE
- FORMATIVE REVIEW
- OTHER (SPECIFY BELOW):

II. BIOMETRICS

STATISTICAL EVALUATION BRANCH

- TYPE A OR B NDA REVIEW
- END OF PHASE II MEETING
- CONTROLLED STUDIES
- PROTOCOL REVIEW
- OTHER:

- DISSOLUTION
- BIOAVAILABILITY STUDIES
- PHASE IV STUDIES

STATISTICAL APPLICATION BRANCH

- CHEMISTRY REVIEW
- PHARMACOLOGY
- BIOPHARMACEUTICS
- OTHER:

- DEFICIENCY LETTER RESPONSE
- PROTOCOL-BIOPHARMACEUTICS
- IN-VIVO WAIVER REQUEST

III. BIOPHARMACEUTICS

- PHASE IV SURVEILLANCE/EPIEDEMOLOGY PROTOCOL
- DRUG USE e.g. POPULATION EXPOSURE,
  ASSOCIATED DIAGNOSES
- CASE REPORTS OF SPECIFIC REACTIONS (List below)
- COMPARATIVE RISK ASSESSMENT ON GENERIC DRUG GROUP

IV. DRUG EXPERIENCE

- REVIEW OF MARKETING EXPERIENCE, DRUG USE AND SAFETY
- SUMMARY OF ADVERSE EXPERIENCE
- POISON RISK ANALYSIS

V. SCIENTIFIC INVESTIGATIONS

- CLINICAL
- PRECLINICAL

COMMENTS/SPECIAL INSTRUCTIONS: CBE Supp-044 provides for the following: a batch size increase for the 60 mg/0.6 mL, 60 mg/0.8 mL and 100 mg/1.0 mL Lovenox Injection pre-filled syringes, from ___ to ___. I am consulting the complete submission (5 volumes) Please review. Dr. Joseph Sieczkowski is the review chemist. Thanks, Karen Oliver, Project Manager

SIGNATURE OF REQUESTER:  
METHOD OF DELIVERY (Check one):
- MAIL
- HAND

SIGNATURE OF RECEIVER:  
SIGNATURE OF DELIVERER:
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
-----------------
Karen Oliver
6/12/01 12:33:03 PM